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Murine MSCs are a readily available source of adult stem cells enabling extensive in vitro study of this cell population. 
MSCs have been described as multipotent, and have been proven capable of differentiation into several connective 
tissue types. Furthermore some studies have suggested an ability to differentiate into non-connective tissue cell types 
such as the cardiomyocyte. The aim of this study was to differentiate murine MSCs toward cardiac lineage with the 
commonly used method of culture with 5’ Azacytidine. Critically, baseline analysis of gene expression of passage four 
MSCs demonstrated expression of key cardiac markers including cardiac troponin T and I, and the ryanodine receptor. 
Furthermore, expression analysis of these genes changed with time in culture and passage number. However, there 
was no significant alteration when cells were subjected to a differentiation protocol. This study therefore highlights 
the importance of analyzing baseline cells extensively, and indicates the limitations in extrapolating data for comparison 
between species. Furthermore this data brings into question the efficacy of cardiac differentiation using MSCs.
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  Mesenchymal stem cells (MSCs) are defined using three 
key parameters; firstly adherence to tissue culture plastic, 
a simple and effective method of cell isolation; secondly 
conforming to specific surface antigen expression and fi-
nally, ability for multipotent differentiation in vitro (1). In 
recent years, aided by ease of isolation and culture, this 
cell population has been extensively studied in relation to 
use of these adult stem cells as a therapeutic agent and 
source of cellular precursors for tissue regeneration.
  Rodent modeling has created the foundation for re-
search in this field, however characterization of MSCs is 
challenging given the wealth of markers available (2). A 
number of studies across several species have shown that 
MSCs are capable of differentiating along three standard 
routes namely osteoblast, adipocyte, and chondrocyte cell 
types (2-7). Furthermore there is a suggestion that these 
mesodermal lineage cells have the ability to differentiate 
into non-connective tissue cell types such as neuronal, 
hepatocyte and cardiomyocyte (8-13).
  In this study we obtained commercially available mur-
ine MSCs (Invitrogen) and characterized their marker ex-
pression following cardiac differentiation, and subsequent-
ly at different passage number. Murine MSCs were pur-
chased from Invitrogen (Cat. No. 510502-01) and cultured 
in murine MSC media; DMEM low glucose containing 
Glutamax-I (Invitrogen), with 10% MSC qualified foetal 
bovine serum (FBS) (Invitrogen Cat. No. 12662-011) and 
100 U/ml penicillin G and 100μg/ml streptomycin (both 
Invitrogen). Cells were plated at a cell density of 5,000 
cells per cm2 at 37oC, 5% CO2 and exhibited a typical 
MSC morphology with flattened adherent cells with multi-
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Fig. 1. Morphology and CD44 staining of Murine MSCs. Murine MSCs resembled other described MSCs in culture, with flattened morphol-
ogy, and multiple jagged projections (A, magnification ×200 and B, magnification ×400). Murine MSCs were positive for CD44 (C, magnifi-
cation ×400). Negative controls were run alongside using secondary antibody alone (D, magnification ×400).
ple jagged projections (Fig. 1A, B). Cells were passaged 
every 3∼4 days, and no evidence of senescence was ob-
served until passage 18 when experiments were stopped; 
and no difference in cell morphology or passage behaviour 
was noted. Cells were characterized and found to be CD44 
positive by both immunofluorescence (Fig. 1C, D) and 
RT-PCR (Fig. 2) and CD45 negative by RT-PCR (data not 
shown). Total RNA was extracted from cell pellets using 
the RNeasyⓇ mini-kit (Qiagen), and 500 ng reverse tran-
scribed using OmniscriptⓇ RT (Qiagen). Primer pairs for 
murine markers were designed based on published se-
quences (NCBI) using Primer 3 software (http://primer3. 
sourceforge.net/) (Table 1). Bands of corresponding size 
were sequenced and compared to the genome. Immunoflu-
orescence was performed on early passage monolayer 
MSCs grown on 4-well chambered slides (Corning) using 
rabbit polyclonal to CD44 (Abcam, Ab65829) at 1：200, 
and secondary antibody Alexaflour 488 goat anti-rabbit 
IgG (H+L) (Invitrogen, A-11034) at 1：500.
  Murine MSCs were exposed to a cardiac differentiation 
protocol using the demethylating agent 5’ Azacytidine (5’ 
AZA). 5×104 cells in 0.5 ml media was added to each well 
of a 24-well plate with standard MSC media, and 3μM 
5’AZA (Sigma) was added to the differentiated wells every 
3 days for 3 weeks. Harvests of triplicate wells were taken 
at days 0, 7, 14 and 21 and RNA was subsequently ex-
tracted, and used for semi-quantitative RT-PCR using 100 
ng RNA (Fig. 2). Vascular endothelial growth factor ex-
pression appeared to remain high and unchanged during 
the differentiation protocol in both test and control MSCs, 
compared to day 0. NKx2.5 remained at a similar ex-
pression level to day 0 across all the samples except for 
day 21 undifferentiated, where expression levels appeared 
lower. GATA 4 expression increased in differentiated sam-
ples over time. Flk-1 appeared to have higher expression 
levels in differentiated samples at all time points com-
pared to day 0 and control cells. Smooth muscle actin 
(SMA) appeared to decrease in all samples when com-
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Fig. 2. Marker expression analysis of Murine MSCs during cardiac
directed differentiation. Semi-quantitative RT-PCR analysis of mark-
ers expressed at time points of days 0, 7, 14 and 21 were com-
pared against differentiated (D) and undifferentiated (U) cells. 
VEGF: vascular endothelial growth factor; SMA: smooth muscle ac-
tin; CTI: cardiac troponin I; RyR: cardiac ryanodine receptor; 
CNX43: Conexin 43.
Table 1. Murine oligonucleotides
Mouse marker Sequence 5’-3’ Predicted product size
C-Kit Fa: AGG GAT TCC CGG AGC CCA CA 252
Rb: GGG CCT GGA TTT GCT CTT TAA ATG C
Islet 1 F: GGT TTC TCC GGA TTT GGA AT 183
R: CAC GAA GTC GTT CTT GCT GA
NKx2.5 F: GTG AAA CCT GCG TCG CCA CCA T 469
R: TAG ACC TGC GCC TGC GAG AAG A
GATA 4 F: CAA GAT GAA TGG CAT CAA CC 216
R: GGT TTG AAT CCC CTC TTT CC
Flk 1 F: AAG GCG CTG CTA GCT GTC GC 164
R: TCC CGC TGT CCC CTG CAA GT
Cardiac troponin T F: TGT CCA ACA TGA TGC ACT TTG GAG G 165
R: GCT CCT TGG CCT TCT CTC TCA GT
B-adrenergic receptor F: TCC TTC TAC GTG CCC CTG TGC A 440
R: CGC TGG AAA GCC TTG CGA AGT
Cardiac ryanodine receptor F: GTT CTG CAG TGC ACG GCG ACC 268
R: GGC CTC CAC CTT GAG CAG TCT TCA T
Cardiac troponin I F: CAG CGA TGC GGC TGG GGA AC 297
R: CGA GCG TGA AGC TGT CGG CA
Vascular endothelial growth factor F: GTG CAC TGG ACC CTG GCT TT 300
R: CCG CAT GAT CTG CAT GGT GAT GT
pared to day 0, with a more pronounced drop in ex-
pression seen in the undifferentiated samples at all 
time-points. Cardiac troponin I (CTI) appeared to increase 
in all samples when compared to day 0. The ryanodine 
receptor was expressed at very low levels in all samples. 
CD44 was expressed in all samples, with a slightly lower 
expression in undifferentiated samples compared to differ-
entiated, and almost no expression seen in day 21 un-
differentiated samples. Connexin 43 (CNX 43) expression 
appeared to be higher in all differentiated and control 
cells when compared to day 0. Murine MSCs did not ex-
press c-kit, a commonly used cardiac stem cell marker, or 
the β1-adrenergic receptor (Beta-1 Ad; data not shown). 
  Our results suggested that murine MSCs may be alter-
ing expression pattern over time, we therefore investigated 
the effects of passage number on the murine MSCs by 
comparing early (passage 4) and late passage (passage 18) 
cells. No alteration in morphology was seen over the time 
period and there was no suggestion of senescence, with 
cell numbers continuing to increase by a magnitude of 2∼
3, even by the later passages. Using 500 ng total RNA and 
semi-quantitative RT-PCR it was seen that several mark-
ers demonstrated alterations in expression level (Fig. 3). 
Firstly it was noted that in this panel of markers we now 
saw both islet 1 and cardiac troponin T (CTT) expression, 
which had not been seen in the day 0 MSCs in the differ-
entiation experiment. This may be explained by the five 
fold increase in total RNA used in the passage difference 
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Table 1. Continued
Mouse marker Sequence 5’-3’ Predicted product size
Von willibrands factor F: GGG TCT GCA ACT GCC CAC CC 160
R: GTG GGG CCC AAT GTT GGC CT
Smooth muscle actin F: GCC CAG CCA GTC GCT GTC AG 180
R: TTA CTC CCT GAT GTC TGG GAC GTC C
CD44 F: AGC ACC TTG GCC ACC ACT CCT A 306
R: AGC TGC AGT AGG CTG AAG GGT T
CD34 F: TGG CCC AGG GTA TCT GCC TGG 212
R: GCT GGG AAG TTC TGT GCT ATT GGC C
CD45 F: CCT TAC CTG CTC GCA CCA CTG AA 419
R: GCT TGC AAG GCC CAG AGT GGA T
Connexin 43 F: ATG AGC AGT CTG CCT TTC GT 249
R: TCT GCT TCA AGT GCA TGT CC
GAPDH F: CAT CAA CGG GAA GTC CAT CT 428
R: GTG GAA GCA GGG ATG ATG TT
C-Kit Fa: AGG GAT TCC CGG AGC CCA CA 252
Rb: GGG CCT GGA TTT GCT CTT TAA ATG C
Islet 1 F: GGT TTC TCC GGA TTT GGA AT 183
R: CAC GAA GTC GTT CTT GCT GA
NKx2.5 F: GTG AAA CCT GCG TCG CCA CCA T 469
R: TAG ACC TGC GCC TGC GAG AAG A
GATA 4 F: CAA GAT GAA TGG CAT CAA CC 216
R: GGT TTG AAT CCC CTC TTT CC
Flk 1 F: AAG GCG CTG CTA GCT GTC GC 164
R: TCC CGC TGT CCC CTG CAA GT
Cardiac troponin T F: TGT CCA ACA TGA TGC ACT TTG GAG G 165
R: GCT CCT TGG CCT TCT CTC TCA GT
B-adrenergic receptor F: TCC TTC TAC GTG CCC CTG TGC A 440
R: CGC TGG AAA GCC TTG CGA AGT
Cardiac ryanodine receptor F: GTT CTG CAG TGC ACG GCG ACC 268
R: GGC CTC CAC CTT GAG CAG TCT TCA T
Cardiac troponin I F: CAG CGA TGC GGC TGG GGA AC 297
R: CGA GCG TGA AGC TGT CGG CA
Vascular endothelial growth factor F: GTG CAC TGG ACC CTG GCT TT 300
R: CCG CAT GAT CTG CAT GGT GAT GT
Von willibrands factor F: GGG TCT GCA ACT GCC CAC CC 160
R: GTG GGG CCC AAT GTT GGC CT
Smooth muscle actin F: GCC CAG CCA GTC GCT GTC AG 180
R: TTA CTC CCT GAT GTC TGG GAC GTC C
CD44 F: AGC ACC TTG GCC ACC ACT CCT A 306
R: AGC TGC AGT AGG CTG AAG GGT T
CD34 F: TGG CCC AGG GTA TCT GCC TGG 212
R: GCT GGG AAG TTC TGT GCT ATT GGC C
CD45 F: CCT TAC CTG CTC GCA CCA CTG AA 419
R: GCT TGC AAG GCC CAG AGT GGA T
Connexin 43 F: ATG AGC AGT CTG CCT TTC GT 249
R: TCT GCT TCA AGT GCA TGT CC
GAPDH F: CAT CAA CGG GAA GTC CAT CT 428
R: GTG GAA GCA GGG ATG ATG TT
aForward primer, breverse primer.
experiment, and therefore may indicate that RNA input 
is important when examining genes. Interestingly murine 
MSCs expressed CD34. It is generally accepted that MSCs 
should not express CD34 (1), however differences in CD34 
expression has been observed in murine MSC populations, 
with interesting variation in the angiogenic potential be-
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Fig. 3. Murine MSC marker expression changes with passage 
number. Murine MSCs were analysed using semi-quantitative 
RT-PCR for marker expression at early passage (passage 4; p(4)) and
late passage (passage 18; p(18)). Markers with expression level var-
iation noted with names in red. VEGF: vascular endothelial growth
factor; SMA: smooth muscle actin; CTT: cardiac troponin T; CTI: 
cardiac troponin I; RyR: cardiac ryanodine receptor; CNX43: 
Conexin 43.
tween positive and negative populations (14). Furthermore 
we noted an increase in expression of islet 1, GATA 4, CTI, 
CTT, CD44 and CXN43, and a decrease in the expression 
of SMA from early to late passage respectively. These re-
sults taken in isolation could suggest movement toward a 
cardiac lineage expression profile simply as a function of 
culture duration. Key differences in MSC expression of 
cardiac lineage genes may be inadvertently used as proof 
of differentiation when we take into consideration that 
murine MSCs used in this study expressed genes deemed 
to be indicative of a cardiac phenotype at baseline and lev-
els of expression altered by duration of culture alone. 
Alteration in gene expression by passage number has been 
reported previously in murine MSCs (15) and is therefore 
an important finding when analyzing results.
  These results highlight the importance of interpretation 
of differentiation data, and in defining differentiation cri-
teria prior to the experiment particularly in the context 
of species type and passage number and illustrate the im-
portance of appropriate controls. Rodent MSCs have been 
described capable of cardiac differentiation using 5’ AZA 
based upon cardiac marker expression (16-18). This study 
aims to highlight the importance of fully analyzing base-
line cells prior to experimentation and may warrant the 
need for global marker expression profiling studies. When 
making comparisons between MSC populations it is im-
perative to identify all confounding factors; species differ-
ences, site of MSC isolation, technique for isolation and 
passage number can all have an influence upon variation 
within MSC populations.
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